Neuronetics, Inc.

Neuronetics, Inc. is a global neuroscience company focused on mental health, providing treatment options to patients and healthcare providers. The company's primary product is the NeuroStar Advanced Therapy System, a non-invasive, office-based treatment that uses transcranial magnetic stimulation (TMS). This system creates a pulsed, MRI-strength magnetic field to stimulate specific brain areas linked to mood. The NeuroStar Advanced Therapy System is cleared by the U.S. FDA to treat adult patients with major depressive disorder (MDD) who have not improved with prior antidepressant medication in their current MDD episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder (OCD) and for adolescent patients aged 15-21 with MDD. Additionally, it is FDA-cleared to reduce anxiety symptoms in adult MDD patients who also experience comorbid anxiety symptoms (anxious depression). Neuronetics sells the NeuroStar Advanced Therapy System and related treatment sessions. The company also operates Greenbrook treatment centers across the U.S., which are wholly owned subsidiaries offering NeuroStar Advanced Therapy. These centers also provide SPRAVATO® for adults with treatment-resistant depression or depressive symptoms in adults with MDD experiencing acute suicidal ideation or behavior. Neuronetics estimates that 237,574 global patients have been treated with over 8.5 million of their treatment sessions through December 31, 2025. For the year ended December 31, 2025, the company generated revenues of $149.2 million.